KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback